Neogenomics director Kelly buys $38,000 in common stock

FORT MYERS, FL—Kelly Michael Aaron, a director at NeoGenomics Inc . (NASDAQ:NEO), recently acquired 5,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were purchased on May 27 at $7.60 per share, amounting to a total transaction value of $38,000. The purchase comes as the stock trades near $7.42, having declined nearly 58% over the past six months. According to InvestingPro data, analysts maintain price targets ranging from $8.50 to $15.00. Following this acquisition, Kelly holds 31,755 shares directly.

The shares were acquired through the Michael and Bonnie Kelly Revocable Trust, indicating an indirect ownership nature. This transaction reflects Kelly’s ongoing involvement and investment in NeoGenomics, a prominent player in the field of cancer diagnostics with a market capitalization of approximately $954 million. While currently unprofitable, InvestingPro analysis indicates the company is expected to return to profitability this year. Get deeper insights into insider trading patterns and 10+ additional ProTips with an InvestingPro subscription.

The filing also detailed various stock options held by Kelly, including rights to buy additional shares at different exercise prices, though no new transactions regarding these options were reported in the current filing. Based on InvestingPro’s Fair Value analysis, the stock currently appears to be fairly valued.

In other recent news, NeoGenomics reported its Q1 2025 earnings, with revenue reaching $168 million, which was below the forecasted $171.35 million. Despite this revenue miss, the company achieved an earnings per share (EPS) of $0, surpassing the expected -$0.01. NeoGenomics has also launched the c-MET CDx diagnostic assay for non-small cell lung cancer (NSCLC), which is now available across the U.S. with a 48-hour turnaround time. Additionally, the company recently unveiled its PanTracer Family of genomic profiling tests and the Paletrra spatial proteomics platform at the ASCO 2025 meeting, aiming to advance precision medicine in oncology.

Furthermore, NeoGenomics has fully repaid its $201.25 million convertible debt, showcasing strong financial management. The company continues to focus on expanding its oncology diagnostics portfolio, including the introduction of the PanTracer LBx liquid biopsy test. NeoGenomics has also reaffirmed its full-year revenue guidance, projecting a 13-15% growth, and expects continued growth in next-generation sequencing (NGS) products. Lastly, the company maintained its strategic focus on innovation, with collaborations such as the one with Ultima Genomics to enhance its clinical test offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.